Biotech公司竞争战略与创新发展对策  

Analysis on the Competitive Strategy of Biotech Company′s Development and Innovation Suggestions

作　　者：王世春[1] 程娟 赵忠卫 WANG Shi-chun;CHENG Juan;ZHAO Zhong-wei(Productivity Center of Jiangsu Province,Nanjing 210042,China;Shenzhen Aoqi Biological Medicine Co.,Ltd,Shenzhen 518057,China)

机构地区：[1]江苏省生产力促进中心,江苏南京210042 [2]深圳奥祺生物医药有限公司,广东深圳518057

出　　处：《药物生物技术》2022年第5期441-447,共7页Pharmaceutical Biotechnology

基　　金：江苏省政策引导类计划(软科学研究)(No.BR2021035)。

摘　　要：在政策鼓励和市场需求下,外加技术和资本的助推,国内各种类型的Biotech公司已超过1000家,获批进入临床研究的新分子创新药也已经超过1000个,国内的Biotech公司进入高速爆发和增长期。为了研究Biotech公司竞争战略与创新发展对策,文章比较了Biotech与Biopharma和Big pharma的异同点及各自在中国医药行业的发展现状。从Biotech的升级的可行性方向、升级必备要素和升级的阶段性标志三个方面进行探讨,以波特竞争战略为模型,选取百济神州、微芯生物和再鼎医药分别进行案例分析,总结出业务领先战略、差异化战略和核心战略在Biotech进阶成为Biopharma之路中的体现。文章归纳出Biotech升级为Biophamra必备的六要素:产品、产品全生命周期运营能力、现代公司体系、融资能力、产品的全球化能力以及BD整合能力。而升级发展的重要力量则是依赖科技创新,包括建立快速响应机制、组建创新联合体、融入产业集群发展、施行全球人才战略等。The development of innovative drugs in China is just getting started,with policy encouragement and market demand,coupled with the support of technology and capital,there are more than 1000 biotech companies of various types in China,and more than 1000 new molecular innovative drugs have been approved for clinical research.In nowadays China,biotech companies enter a period of rapid outbreak and growth.In order to research the development stragety and innovation suggestions for biotech companies,this article compares the similarities and differences between Biotech companies,Biopharma companies and Big pharma companies and their respective development status in China′s pharmaceutical industry.The discussion will be conducted from three aspects:the feasibility direction of Biotech′s upgrade,the essential elements of the upgrade,and the stage signs of the upgrade.Using Michael E.Porter′s competitive strategy as a model,BeiGene,Chipscreen,and Zai Lab were selected for case analysis,and summarized the business leadership strategy,differentiation strategy and core strategy in the way of Biotech′s advancement into Biopharma.It also summarizes the six elements necessary for Biotech companies to upgrade to Biophamra companies:products,product life cycle operation capabilities,modern company systems,financing capabilities,product globalization capabilities,and business development integration capabilities.The staged signs of the completion of the upgrade include the approval of the product′s launching market access and sales feedback of the product,and the establishment of a modern enterprise operating system.Refer to innovation suggestions to Biotech comopanies and other high-tech companies to upgrade and improve their competition abilities,the important force of upgrading development is relying on scientific and technological innovation,including the establishment of rapid response mechanism,the establishment of innovation consortium,the integration of industrial cluster development,the implementation of global

关 键 词：BIOTECH 波特模型 医药企业 发展战略 科技创新 快速响应 创新对策 

分 类 号：Q819[生物学—生物工程]